光子计数CT光谱重建鉴别附件高密度病灶有无强化
该回顾性研究纳入38例成人女性附件病灶,以180天内盆腔MRI或超声为参考标准,评估光子计数CT光谱重建的鉴别价值。结果显示,增强与非增强病灶在ΔHU、碘密度、标准化碘密度上均有显著差异。ΔHU≥12.0 HU、ID≥0.4 mg/mL、NID≥8%均达到100%敏感度和95%特异度(AUROC均为0.99),提示可避免部分随访影像。
要点
- 70 keV图像上高密度附件病灶,可用VUE与70 keV衰减差ΔHU≥12 HU判定有强化。
- 碘密度≥0.4 mg/ml或标准化碘密度≥8%提示增强,均达100%敏感度、95%特异度。
- PCCT光谱重建可准确评估高密度附件病灶强化,可能减少后续随访影像需求。
核心结论
- 利用VUE图像的衰减变化和碘定量可在PCCT上以极佳诊断效能区分增强与非增强的高密度附件病灶。
- 在PCCT上准确评估高密度附件病灶强化可能免除后续随访影像的需要。
研究设计与样本
- 回顾性研究,通过PACS检索纳入38例成人女性患者,中位年龄44岁(IQR 37–48)。
- 入组标准为附件病灶在70 keV PCCT图像上>1 cm且>20 HU,且180天内有盆腔MRI或超声作为参考标准。
- 22例为非增强病灶,16例为增强病灶;两名放射科医师在Thin-client软件上独立勾画ROI测量。
诊断标准与关键数值
- 70 keV图像上检测强化的最佳ΔHU阈值为12.0 HU,敏感度100%,特异度95%,AUROC为0.99(95%CI:0.97–1.00)。
- 碘密度阈值0.4 mg/ml的敏感度为100%,特异度为95%,AUROC为0.99(95%CI:0.97–1.00)。
- 标准化碘密度阈值8%的敏感度为100%,特异度为95%,AUROC为0.99(95%CI:0.96–1.00)。
- 两名放射科医师测量的组内相关系数ICC为0.74(95%CI:0.56–0.86)。
临床应用与阅片要点
- 阅片时对70 keV图像上高密度附件病灶,应同时调阅VUE图像计算ΔHU并查看碘图碘密度及标准化碘密度。
- 以ΔHU≥12 HU、ID≥0.4 mg/ml或NID≥8%作为强化判定参考,可避免主观判断增强的差异。
- 标准化碘密度以主动脉强化为参照,可减少对比剂剂量和循环时间差异对碘定量结果的影响。
局限性
- 回顾性单中心研究,样本量小,共38例患者。
- 参考标准为180天内的盆腔MRI或超声,并非组织病理学确诊。
- 观察者间一致性ICC为0.74(95%CI:0.56–0.86),提示测量存在一定观察者间变异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Hyperdense adnexal lesions on conventional CT often necessitate follow-up imaging. Photon counting CT (PCCT) allows for the generation of virtual unenhanced (VUE) and iodine map images. The purpose was to investigate the utility of PCCT spectral reconstructions to distinguish enhancing from nonenhancing hyperdense adnexal lesions.
METHODS: A retrospective Picture Archiving and Communication System (PACS) search identified adult women with adnexal lesions on contrast-enhanced PCCT and with pelvic MRI or ultrasound within 180 days characterizing the lesion, the reference standard. Patients with adnexal lesions > 1 cm and > 20 Hounsfield Units (HU) on 70 keV PCCT images were included. Two radiologists drew region-of-interest measurements independently on adnexal lesions on thin-client software. Attenuation on VUE and 70 keV images, iodine density (ID), and iodine density normalized to aortic enhancement (NID) were recorded from the same region-of-interest. Attenuation change (ΔHU) from VUE to 70 keV was computed. Wilcoxon rank-sum test was used to compare ID, NID, and ΔHU for enhancing versus nonenhancing lesions. Receiver-operating characteristic (ROC) curves were used to determine optimal thresholds for enhancement. Inter-reader agreement was assessed with intraclass correlation coefficients (ICC).
RESULTS: 38 women (median [Interquartile Range (IQR)] age: 44[37,48]) were included. 22 had nonenhancing and 16 had enhancing lesions. ΔHU for enhancing and nonenhancing lesions was 27[24,37]HU and 2[-1,5]HU, respectively (p<.001). ID of enhancing and nonenhancing lesions was 1.15[0.98,1.60] mg/ml and 0.05[-0.08,0.18] mg/ml, respectively (p<.001). NID of enhancing and nonenhancing lesions was 22[14,29]% and 1.0[-1.0,3.0]%, respectively (p<.001). The optimal ΔHU for detecting enhancement at 70 keV was 12.0HU with 100% sensitivity and 95% specificity (Area Under the Curve (AUROC) = 0.99[95% Confidence Interval (CI): 0.97,1.00]). 0.4 mg/mL ID and 8% NID both had 100% sensitivity and 95% specificity (AUROC = 0.99[95%CI: 0.97,1.00]; AUROC = 0.99[95% CI: 0.96,1.00]; respectively). ICC[95% CI] was 0.74[0.56,0.86].
CONCLUSION: Attenuation change utilizing VUE images and iodine quantification can differentiate enhancing from nonenhancing hyperdense adnexal lesions at PCCT with excellent diagnostic performance. Accurate assessment of hyperdense adnexal lesion enhancement on PCCT may negate the need for follow-up imaging.
引用
- Rigau, Parrott, Bansal, et al. Distinguishing enhancing from non-enhancing hyperdense adnexal lesions with spectral reconstructions at photon counting CT. Abdom Radiol (NY). 2026. PMID: 42622831. doi:10.1007/s00261-026-05733-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。